Objective-Increased levels of circulating tissue factor (TF) in the form of microparticles increase the risk of thrombosis.
I n addition to its role in hemostasis, tissue factor (TF) has nonhemostatic functions that arise from its ability to activate various intracellular signaling pathways, 1-3 leading to changes in cell proliferation, 4 cell migration, 5 and gene expression. 6 It has previously been shown that TF:FVIIamediated activation of the extracellular signal regulated kinase (ERK)1/2 pathway results in smooth muscle cell proliferation. 4 Furthermore, it has been shown that incubation of endothelial cells (EC) with recombinant TF alone induces cellular proliferation, together with an associated upregulation of cyclin D1 expression in these cells. 7 Recently, a number of reports have demonstrated the ability of TF to interact with cell surface integrins, 8 -11 resulting in diverse cellular outcomes, including the activation of cell signaling pathways, cell migration, and capillary tube formation. 8, 9, 11 The binding of cell surface TF to ␤1-integrin, ␣3-integrin, and ␣6-integrin on endothelial cells was shown to require FVIIa, 9 whereas binding of alternatively spliced TF (asTF) to ␣v␤3-integrin and ␣6␤1-integrin was shown to be independent of FVIIa. 11 We have previously demonstrated the inter-action of lipidated recombinant TF with the ␤1-integrin subunit and shown that this was independent of FVIIa. 10 However, the mechanism by which TF interacts with integrins remains unclear.
TF can be released from cells in the form of microparticles, which constitute a proportion of circulating TF. 12 TFcontaining microparticles may be released from various cells, including monocytes/macrophages, 13 endothelial cells, 13 and smooth muscle cells. 14 These microparticles are highly procoagulant because of the presence of TF and phosphatidylserine, and elevations in the level of circulating microparticleassociated TF have been linked to an increased risk of thrombosis in a number of vascular conditions. [15] [16] [17] [18] Furthermore, it has been demonstrated that microparticles can transfer TF between different cell types. 19, 20 It has previously been shown that the incubation of human umbilical vein endothelial cells (HUVEC) with exogenous recombinant TF results in the induction of a number of cell signaling pathways, 21 despite the lack of protease-activated receptor-2 (PAR2) in these cells. Moreover, it was demonstrated that this form of TF interacts with the cell surface. 7, 10, 21 This study is an attempt to further elucidate the mechanisms by which exogenous TF induces endothelial cell proliferation. Throughout this investigation, 2 forms of "exogenous" TF, lipidated recombinant TF and TF-containing cell-derived microparticles, have been used at concentrations of TF corresponding to those found in healthy individuals (5 to 10 pmol/L) or in plasma of patients with cardiovascular disease (50 to 200 pmol/L). 22, 23 We provide evidence that both recombinant TF and microparticle-associated TF increase endothelial cell proliferation through a mechanism that involves ERK1/2 activation and requires cell surface ␤1integrin but is independent of FVIIa.
Methods

Materials
Polyclonal antihuman TF antibody, lipidated recombinant full-length TF, nonlipidated recombinant TF, recombinant FVIIa, and recombinant FXa were purchased from American Diagnostica, Inc. The recombinant ␤1-integrin peptide (amino acids 579 to 799) was obtained from ProSpec-Tany TechnoGene Ltd. For a complete list of reagents, please see supplemental material, available online at http://atvb.ahajournals.org.
Cell Culture
Human coronary artery endothelial cells (HCAEC) (PromoCell) were cultured under 5% CO 2 at 37°C in endothelial cell growth medium (PromoCell) containing 5% (vol/vol) FCS and growth supplements. For serum-free experiments, the FCS concentration was gradually reduced, and finally the cells washed with PBS and placed in serum-free medium supplemented with epidermal growth factor (10 ng/mL) and basic fibroblast growth factor (20 ng/mL).
Proliferation and Apoptosis Assays
Cell proliferation was measured using an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium)-based assay and cell numbers confirmed by staining with crystal violet. Apoptosis was measured using the DeadEnd Fluorimetric TUNEL assay (Promega). For details, please see supplemental material.
SDS-PAGE and Western Blot Analysis
Whole-cell lysates (10 g protein) were separated by SDS-PAGE and analyzed by Western blotting using antibodies against total or phosphorylated forms of ERK1/2, c-Jun N-terminal kinase-1/2, or p38. For details, please see supplemental material.
Microparticle Preparation
Cell-derived microparticles were prepared by ultracentrifugation as described before. 10 The concentrations of microparticles were determined using the Zymuphen microparticle determination kit (Hyphen BioMed). TF antigen and activity levels were measured using a TF-ELISA kit (Affinity Biologicals) and 2-stage chromogenic assay, respectively. 24, 25 For details, please see supplemental material.
ERK1/2 Inhibition Using Antisense Oligodeoxynucleotides (ODN)
Sequences for ERK1/2 antisense (5Ј-GCCGCCGCCGCCGCCAT-3Ј), sense (5Ј-ATGGCGGCGGCGGCGGC-3Ј), and scrambled (5Ј-CGCGCGCTCGCGCACCC-3Ј) phosphorothioate-modified ODN were according to a published procedure. 26 The scrambled ODN was synthesized with a 3Ј-fluorescein isothiocyanate group to allow transfection efficiency to be determined by flow cytometry. HCAEC (12.5ϫ10 4 ) were adapted to OptiMEM reduced serum medium and transfected with the ERK1/2 ODN (0.1 mol/L) using Lipofectin according to the manufacturer's instructions. The cells were incu-bated at 37°C for 5 hours and then placed in medium containing 1% (vol/vol) FCS. The cells were incubated at 37°C for 48 hours, adapted to serum-free medium, and used in experiments.
Statistical Analysis
Data are expressed as meanϮSEM. The data were analyzed using the statistical package for the social sciences (SPSS). Significance was determined using 1-way ANOVA, and values of PϽ0.05 were considered to be significant.
Results
Lipidated Recombinant TF and Microparticle-TF Induce Proliferation in HCAEC
To ensure consistency between the microparticle preparations, the concentration of TF antigen and levels of TF activity of the microparticles isolated from TF-transfected and nontransfected ECV304 and HCAEC cells were determined before use (supplemental Table I ). Moreover, the concentration of total released microparticles was consistent between different preparations (0.32Ϯ0.06 nmol/L), and the phosphatidylserine:phosphatidylcholine ratio was consistently 33Ϯ2.4:67Ϯ2.4 as determined by thin-layer chromatography. The ratio of microparticle concentration to number of cells was 1.5Ϯ0.2 pmol microparticles per 10 6 cells, and the total concentrations of microparticles from TF-transfected and nontransfected cells were similar. Furthermore, the absence of the exosome marker Tsg101 in the microparticle preparations from both ECV304 and HCAEC suggests that the microparticles were ectosomes derived from the cell surface rather than exosomes (supplemental Figure IA) . 27 Incubation of HCAEC with TF-containing microparticles (200 pmol/L) resulted in rapid depletion of TF from the culture media (supplemental Figure IB) , indicating microparticle uptake by the cells. Incubation of HCAEC with high concentrations of lipidated recombinant TF (50 to 200 pmol/L) resulted in increases in cell proliferation of up to 82% above that of the untreated control ( Figure 1A ). Addition of ECV304-derived microparticles ( Figure 1B ) or HCAECderived microparticles ( Figure 1C ) containing 100 to 200 pmol/L of TF resulted in increases in cell proliferation of up to 37%, whereas corresponding concentrations of controlmicroparticles had little influence. Preincubation of recombinant TF or TF-microparticles (100 pmol/L) with an anti-TF polyclonal antibody (100 g/mL) reduced cell proliferation in response to all forms of exogenous TF. In contrast, nonlipidated recombinant TF or a mixture of phosphatidylserine:phosphatidylcholine (30:70) alone had no measurable influence on cell proliferation (supplemental Figure IIA) . TF-containing microparticles (100 pmol/L TF) isolated from the plasma of patients with cardiovascular disease (Innovative Research. Inc.) also induced proliferation of endothelial cells, which was reduced by differing amounts in the different samples by preincubation of the microparticles with an anti-TF polyclonal antibody (supplemental Figure IIB) . Incubation of HCAEC with lipidated recombinant TF (100 pmol/L) or cell-derived microparticles did not induce cellular apoptosis (supplemental Figure III) .
Lipidated Recombinant TF and Microparticle-TF Induce Activation of Mitogen-Activated Protein Kinase Cell Signaling Pathways
To elucidate the signaling pathways involved in the induction of endothelial cell proliferation by exogenous TF, the activation of the mitogen-activated protein kinase pathways was examined. Incubation of HCAEC with lipidated recombinant TF (100 pmol/L) resulted in ERK1 phosphorylation, which peaked at 30 minutes after treatment (Figure 2A ). Furthermore, incubation of cells with lipidated recombinant TF (100 pmol/L) resulted in JNK1 phosphorylation, which peaked at the later time point of 50 minutes ( Figure 2B ). No phosphorylation of p38 was detected in any of the samples (data not shown). HCAEC-derived microparticles containing 200 pmol/L of TF induced ERK1 phosphorylation, whereas control microparticles at similar microparticle densities had little influence ( Figure 2C ).
Inhibition of ERK1/2 Suppresses Lipidated Recombinant TF and Microparticle-TF-Induced Cell Proliferation
Inhibition of ERK1/2 phosphorylation before incubation of cells with lipidated recombinant TF (100 pmol/L) was achieved by preincubation of HCAEC with the mitogenactivated protein kinase kinase inhibitor PD98059 (15 to 50 mol/L) for 30 minutes, and inhibition of the phosphorylation of the JNK substrate c-Jun was achieved by preincubation with SP600125 (60 nmol/L) for 30 minutes (supplemental Figure IVA ). Incubation of HCAEC with PD98059 (15 to 50 mol/L) completely inhibited cell proliferation in response to lipidated recombinant TF (100 pmol/L) ( Figure  3A ), whereas inclusion of SP600125 (20 to 60 nmol/L) showed a dose-dependent decrease in cell proliferation, inhibiting cell proliferation at 60 nmol/L compared with cells treated with TF (100 pmol/L) alone ( Figure 3B ). Preincubation of HCAEC with PD98059 (50 mol/L) also reduced cell proliferation in response to HCAEC-derived microparticles containing TF (200 pmol/L), whereas inclusion of SP600125 (60 nmol/L) had a marginal effect (supplemental Figure  IVB) . Furthermore, inclusion of PD98059 alone (50 mol/L) modestly reduced cell numbers compared with the untreated sample, which was attributed to a small increase in cellular apoptosis observable in the presence of high concentrations of this inhibitor (supplemental Figure III) .
To confirm the data obtained using PD98059, HCAEC were transfected with ERK1/2 antisense ODN (optimized to 0.1 mol/L) (supplemental Figure VA) to inhibit the expression of ERK1/2. Optimal suppression of ERK1/2 expression following transfection of HCAEC with ERK1/2 antisense ODN (0.1 mol/L) was achieved at 48 hours compared with nontransfected cells, whereas JNK expression remained unaffected ( Figure 3C ). Furthermore, sense and scrambled ODN (0.1 mol/L) had no effect on ERK1/2 expression (supplemental Figure VB) . Transfection efficiency of the cells following transfection of HCAEC with the 3Ј-fluorescein isothiocyanate-labeled scrambled ODN (0.1 mol/L) was determined to be 85% using flow cytometry (data not shown). Transfection of HCAEC with ERK1/2 antisense ODN prevented the induction of cell proliferation in response to lipidated recombinant TF (100 pmol/L) ( Figure 3D ). In contrast, transfection of cells with ERK1/2 sense ODN had no measurable influence on TF-mediated cell proliferation.
Induction of HCAEC Proliferation by Recombinant TF and Microparticle-TF Does Not Require FVIIa
Examination of HCAEC revealed no detectable surface TF expression or activity as determined by flow cytometry and the 2-stage chromogenic assay, respectively (data not shown). In addition, the expression of PAR1 and PAR2 in HCAEC was confirmed using RT-PCR (supplemental Figure VIA) . Incubation of HCAEC with recombinant FVIIa (5 nmol/L) and FXa (10 nmol/L) together with lipidated recombinant TF (100 pmol/L) had no additional influence on TF-mediated proliferation ( Figure 4A ). The enzymatic activities of recombinant FVIIa and FXa were confirmed using chromogenic substrates. Furthermore, preincubation of cells with an inhibitory anti-FVIIa antibody (30 g/mL) ( Figure 4A ), or the inhibitory anti-PAR2 antibody SAM11 (25 g/mL) (supplemental Figure VIB) , did not reduce TF-mediated cell proliferation. The addition of recombinant FVIIa (5 nmol/L) alone or recombinant FXa (10 nmol/L) alone had no effect on cell proliferation ( Figure 4A ). Preincubation of TF-containing microparticles with an inhibitory anti-FVIIa antibody also did not reduce cell proliferation in response to TF-containing microparticles ( Figure 4B ). These results were mirrored in ERK1 phosphorylation, because the incubation of HCAEC or HCAEC-derived microparticles with the anti-FVIIa antibody did not reduce the level of ERK1 phosphorylation in response to either lipidated recombinant TF ( Figure 4C ) or microparticle-associated TF ( Figure 4D ).
Induction of HCAEC Proliferation by Recombinant TF and Microparticle-TF Involves an Interaction With ␤1-Integrin
Because TF has been shown to interact with integrins, the possibility that exogenous TF activates signaling through integrins was examined. The expression of ␤1-integrin and ␤3-integrin on HCAEC was examined by flow cytometry, and HCAEC were found to express high levels of ␤1-integrin (90%) and lower levels of ␤3-integrin (32%) (data not shown). A peptide corresponding to amino acids 579 to 799 of ␤1-integrin was used to competitively inhibit the binding of exogenous TF to cell surface ␤1-integrin. Preincubation of lipidated recombinant TF (100 pmol/L) with the ␤1-integrin peptide (0.02 to 1 nmol/L) reduced TF-mediated cell proliferation in a dose-dependent manner ( Figure 4E ). Concurrent with the reduced rate of cell proliferation, incubation of HCAEC with recombinant TF (100 pmol/L) preincubated with the ␤1-integrin peptide (1 nmol/L) reduced TF-mediated ERK1 phosphorylation ( Figure 4C) , and a similar result was observed with TF-containing microparticles (200 pmol/L TF) ( Figure 4D ). An inhibitory anti-␣3-integrin antibody also reduced recombinant TF-mediated HCAEC proliferation, whereas blocking ␤3-integrin or ␣6-integrin had no significant influence on recombinant TF-mediated increases in cell proliferation (supplemental Figure VIC) . In addition, ERK1 phosphorylation in response to lipidated recombinant TF (100 pmol/L) was unaltered by preincubation of HCAEC with antibodies against ␤3-integrin, ␣3-integrin, or ␣6-integrin (data not shown). The ␤1-integrin peptide (1 nmol/L) also significantly reduced cell proliferation ( Figure 4B ) and ERK1 phosphorylation ( Figure 4D ) in response to TF-containing microparticles derived from HCAEC. Preincubation of the ␤1-integrin peptide (1 nmol/L) with plasma-derived microparticles from patients with cardiovascular disease reduced cell proliferation in response to the microparticles in 2 of the samples (supplemental Figure IIB) .
Influence of TF-Containing Microparticles From Other Vascular and Blood Cells on HCAEC Proliferation
Microparticles were isolated from activated THP-1 cells (monocytes), isolated peripheral blood mononuclear cells, and human coronary artery smooth muscle cells. TFcontaining microparticles (100 pmol/L TF) from these cells induced HCAEC proliferation to a similar extent as HCAECderived TF-containing microparticles and was partly reduced by preincubation of the microparticles with an anti-TF antibody (supplemental Figure VII) .
Discussion
Throughout this study, lipidated recombinant full-length TF was used to eliminate the influence of other proteins. In addition, cell-derived microparticles from primary endothelial cells and patient plasma-derived microparticles were used as a model of TF-containing microparticles. TF-containing microparticles from the ECV304 cell line were also used in initial experiments ( Figure 1B) and showed a similar pattern of inducing cell proliferation compared with microparticles derived from primary endothelial cells ( Figure 1C) , which were used thereafter.
In this investigation both lipidated recombinant TF and TF-containing microparticles induced proliferation in coronary artery endothelial cells through activation of the ERK1/2 pathway. A previous study has demonstrated that TF:FVIIa activation of the ERK1/2 pathway is capable of inducing proliferation in smooth muscle cells, 4 whereas our studies have shown that recombinant TF induces the proliferation of HUVEC, 7 as well as the activation of various cell signaling pathways. 21 In an extension to these studies, here, we have shown the ability of microparticle-associated TF and recombinant TF to induce signaling in endothelial cells, and the data presented further support the role of exogenous TF in promoting endothelial cell proliferation. Lipidated recombinant TF showed a greater ability to induce cell proliferation than the same concentrations of TF in cell-derived microparticles. This may be due to a proportion of the TF in the microparticles already being associated with integrins or the presence of other proteins within the microparticles that may modulate these processes. Furthermore, the rate of cell proliferation varied between the different patient plasmaderived microparticle samples, even though the TF concentration was the same, which may be explained by the heterogeneous nature of these microparticles. In addition, TF-containing microparticles isolated from other vascular and blood cells (THP-1 cells, isolated peripheral blood mononuclear cells, and human coronary artery smooth muscle cells) induced proliferation in HCAEC, which was reduced by preincubation of the microparticles with anti-TF antibody, further supporting the role of TF in the induction of endothelial cell proliferation. In contrast, nonlipidated recombinant TF did not induce cell proliferation (supplemental Figure IIA) , indicating the requirement for exogenous TF to be in phospholipids. It is known that TF may be transferred between cell types by microparticles. 19, 20 Furthermore, lipidated recombinant TF has been shown to be incorporated into the cell membrane. 7, 10 It is therefore likely that the phospholipid component assists the fusion of microparticles with the cell membrane, resulting in the incorporation of TF into the cell membrane. The uptake of microparticles by HUVEC has previously been demonstrated. 27 Moreover, the rapid depletion of TF from the media (supplemental Figure IB) suggests uptake of TF-containing microparticles by HCAEC. How-ever, a role for the ligand-mediated interaction of TF within microparticles and cell surface integrins in incorporating TF into the cell membrane cannot be ruled out.
Although HCAEC were found to express PAR2, the ability of lipidated recombinant TF and microparticle-associated TF to induce cell proliferation did not require FVIIa. Furthermore, inclusion of an inhibitory PAR2 antibody did not prevent TF-mediated cell proliferation. Together, these data indicate that exogenous TF is capable of inducing cell proliferation through a protease-independent mechanism. It has been reported that endothelial cells possess a cell-surface ligand for binding to TF. 28 More recent studies have shown that cell surface TF can interact with ␣3␤1-integrin and ␣6␤1-integrin on endothelial cells. 9 Additionally, it has been shown that in epithelial cells and HUVEC, the interaction between cell surface TF and ␤1-integrin is enhanced by the presence of FVIIa, independently of FVIIa activity and PAR2 signaling, whereas in cancer cells, the interaction between cellular TF and integrins is constitutive. 9 A recent study has also shown that asTF can interact with ␣v␤3-integrin and ␣6␤1-integrin on HUVEC or an endothelial cell line, resulting in endothelial cell migration and capillary tube formation by a FVIIa-independent mechanism. 11 These reports further support our findings that TF can interact with integrins independently of FVIIa. In fact, we have previously shown that recombinant TF binds to the surface of breast cancer cells through direct binding to the ␤1-integrin subunit, and that this interaction was reduced by preincubation of cells with a polyclonal antibody directed against amino acids 579 to 799 of ␤1-integrin. 10 Therefore, in this study, a recombinant ␤1-integrin peptide corresponding to amino acids 579 to 799 of ␤1-integrin was used to competitively inhibit the binding of exogenous TF to cell surface ␤1-integrin. This ␤1-integrin peptide corresponds to the C terminus of ␤1-integrin and includes the 4th epidermal growth factor domain and ␤-tail domain of the extracellular domain of ␤1-integrin, as well as the transmembrane and cytoplasmic domains of ␤1integrin. 29 The reduction in cell proliferation and ERK1 phosphorylation in response to both recombinant and microparticle-TF preincubated with this peptide suggests the presence of a novel binding site for exogenous TF within amino acids 579 to 799 of ␤1-integrin and that this interaction is required for TF-mediated proliferation of endothelial cells. Moreover, preincubation of patient plasma-derived microparticles with the ␤1-integrin peptide reduced cell proliferation to differing extents in the 3 patient samples. As previously mentioned, these variations may be a result of the heterogeneous nature of these microparticles, which may also be responsible for different levels of ␤1-integrin within the patient-plasma microparticles. Furthermore, patient-plasma microparticles are likely to be derived from other cell types in addition to endothelial cells, such as macrophages, platelets, and smooth muscle cells, 13, 14 and therefore contain different combinations of integrin subunits with which TF may interact. In addition, endothelial cell proliferation and ERK1 phosphorylation in response to exogenous TF did not require ␤3-integrin or ␣6-integrin, whereas ␣3-integrin was partially involved in cell proliferation. In contrast to our data using recombinant full-length TF or microparticle-associated TF, it has been shown that asTF is not capable of inducing proliferation in endothelial cells and does not interact with ␣3␤1integrin. 11 However, the interaction of asTF with ␣v␤3integrin and ␣6␤1-integrin has been shown to induce cell migration and tube formation, respectively. 11 These differences may be due to the structure of asTF, because asTF lacks the cytoplasmic and transmembrane domains, as well as part of the extracellular domain of full-length TF, 30 and therefore may interact with integrins in a different conformation 11 and have different cellular outcomes compared with full-length exogenous TF. Furthermore, both asTF 11 and exogenous TF 7, 24 have been shown to induce capillary tube formation. Because endothelial cell proliferation is essential for angiogenesis, it would be interesting to examine the influence of microparticle-associated TF on angiogenesis in coronary artery endothelial cells. In conclusion, the binding of fulllength exogenous TF to ␤1-integrin provides a potentially novel mechanism for FVIIa-independent induction of endothelial cell proliferation by recombinant or microparticleassociated TF.
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